Answers are grounded in this paper and cite their sources.
Nanopharmaceuticals are generally successful at laboratory scale, but once production levels rise, their quality suffers, and the reasons for this are seldom explored in relation to monitoring and regulatory requirements. This critical review considers 90 peer-reviewed sources, 77 of which are published from 2020 onward, and explores the relationship between formulation composition, process conditions, particle attributes, in-process monitoring, and regulatory expectations during scale-up. The size, polydispersity, payload integrity and storage stability of lipid nanoparticles, liposomes, polymeric nanoparticles, nanoemulsions and nanocrystals respond differently to changes in mixing, shear, filtration time and freezing history. Quality-by-design studies rarely report design spaces at production scale and most process analytical technology work is focused on particle size, while encapsulation, payload integrity and lipid quality are still tested offline. Nanomedicines are regulated on a case-by-case basis in regulatory documents and no harmonized comparability pathway exists. An unvalidated framework is presented in the review linking material attributes, process parameters, quality attributes, monitoring tier and comparability evidence through a decision matrix and decision-flow diagram. The framework identifies scale sensitive, history sensitive and material sensitive attributes and assigns a monitoring and control strategy to each of them. The priority research needs are inline methods for payload integrity, scale-transferable design spaces, validated digital models and agreed comparability criteria. The proposals have to be tested in prospective real manufacturing programs.
No takes yet. Share an insight, caveat, or question.
Arbaz Khan (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: